Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Trial of Evaluation of the Safety and Efficacy of Treatment With γ-globin Reactivated Autologous Hematopoietic Stem Cells in Subjects With β-thalassemia Major

Next Previous
Trial Profile

An Open Label Trial of Evaluation of the Safety and Efficacy of Treatment With γ-globin Reactivated Autologous Hematopoietic Stem Cells in Subjects With β-thalassemia Major

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BRL 103 (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 Jul 2023 Status changed from not yet recruiting to suspended.
  • 14 Feb 2023 Planned initiation date changed from 25 Dec 2022 to 25 Dec 2023.
  • 09 Oct 2022 Planned initiation date changed from 8 Sep 2022 to 25 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top